Peptide receptor radionuclide therapy (PRRT) uses a radiolabelled somatostatin analogue such as DOTATATE or DOTATOC to deliver radiation to neuroendocrine tumor cells that express sufficient somatostatin receptors. German university hospitals including Ulm, Heidelberg, Essen and Charité publish PRRT as part of specialist nuclear-medicine care. It is not a generic treatment for every neuroendocrine tumor: receptor expression, tumor biology, previous treatment, organ function and the wider oncology plan all matter.
Somatostatin-receptor expression is a key prerequisite
Ulm explains that well-differentiated neuroendocrine tumors often express somatostatin receptors and that receptor-targeted radionuclide therapy depends on adequate receptor expression. In practice, the German nuclear-medicine team needs appropriate molecular imaging and the complete oncology history before deciding whether PRRT is a reasonable option.
DOTATATE or DOTATOC carries the therapeutic radionuclide
Ulm describes Lu-177-labelled DOTATATE for systemic PRRT, while Essen also documents radiopeptide therapy using somatostatin analogues such as DOTATOC or DOTATATE. The exact compound and protocol are center- and case-specific; patients should not assume that all PRRT programs use an identical regimen.
Organ function and blood counts matter before treatment
Ulm states that sufficient liver, kidney and bone-marrow function are prerequisites for receptor-targeted radionuclide therapy. A treatment request should therefore include recent laboratory data together with the cancer history.
- Exact NET diagnosis and pathology / grading
- Primary tumor site and metastatic sites
- Somatostatin-receptor imaging and original images when available
- Prior surgery and systemic treatments
- Previous radionuclide therapy if any
- Recent blood count
- Kidney and liver function
- Current symptoms and performance status
PRRT is usually planned as a treatment course
German center information describes PRRT as a radionuclide treatment delivered within a specialist program rather than a one-off travel procedure. The number and timing of cycles depend on the selected protocol, response, tolerance and the treating team's plan. International patients should ask for the expected number of visits before arranging repeated travel.
Coordinate PRRT with the multidisciplinary NET plan
PRRT sits within a broader neuroendocrine-tumor pathway that can include surgery, somatostatin analogues, targeted treatment and other local or systemic approaches. A nuclear-medicine consultation should therefore be interpreted together with the oncology or NET team's overall treatment sequence.
Plan monitoring between Germany visits
Before travel, clarify which laboratory tests are required before each cycle, whether interval imaging can be performed at home, how radiation-safety instructions affect travel after treatment and which local clinician will handle symptoms or urgent issues between visits.
Sources and review
This guide was last source-reviewed on 2026-08-30.
- PRRT therapy with Lu-177 DOTATATE — Ulm University Hospital ↗
- PRRT / Lutathera or DOTATOC therapy — Heidelberg University Hospital ↗
- Radiopeptide therapy for somatostatin-receptor-positive tumors — University Hospital Essen ↗
- Nuclear medicine treatment spectrum including PRRT — Charité – Universitätsmedizin Berlin ↗